Zhu Wen-Jun, Chen Bo-Jiang, Zhu Ying-Ying, Sun Ling, Zhang Yu-Chen, Liu Huan, Luo Feng-Ming
Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Laboratory of Pulmonary Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, Sichuan University, Chengdu, Sichuan, China.
PeerJ. 2021 Jun 9;9:e11528. doi: 10.7717/peerj.11528. eCollection 2021.
MicroRNA-30a (miRNA-30a) levels have been shown to increase in the plasma of lung cancer patients. Herein, we evaluated the miRNA-30a levels in the bronchoalveolar lavage fluid (BALF) of lung cancer patients as a potential biomarker for lung cancer diagnosis.
BALF miRNA-30a expression of 174 subjects was quantified using quantitative real-time reverse transcription-polymerase chain reaction and compared between lung cancer patients and control patients with benign lung diseases. Moreover, its diagnostic value was evaluated by performing receiver operating characteristic (ROC) curve analysis.
The relative BALF miRNA-30a expression was significantly higher in the lung cancer patients than in the controls (0.74 ± 0.55 versus 0.07 ± 0.48, respectively, < 0.001) as well as in lung cancer patients with stage I-IIA disease than in those with stage IIB-IV disease (0.98 ± 0.64 versus 0.66 ± 0.54, respectively, < 0.05). Additionally, miRNA-30a distinguished benign lung diseases from lung cancers, with an area under the ROC curve (AUC) of 0.822. ROC analysis also revealed an AUC of 0.875 for the Youden index-based optimal cut-off points for stage I-IIA adenocarcinoma. Thus, increased miRNA-30a levels in BALF may be a useful biomarker for non-small-cell lung cancer diagnosis.
已有研究表明，肺癌患者血浆中的微小RNA-30a（miRNA-30a）水平会升高。在此，我们评估了肺癌患者支气管肺泡灌洗液（BALF）中的miRNA-30a水平，将其作为肺癌诊断的潜在生物标志物。
采用定量实时逆转录-聚合酶链反应对174名受试者的BALF中miRNA-30a的表达进行定量，并在肺癌患者和患有良性肺部疾病的对照患者之间进行比较。此外，通过绘制受试者工作特征（ROC）曲线分析来评估其诊断价值。
肺癌患者BALF中miRNA-30a的相对表达显著高于对照组（分别为0.74±0.55和0.07±0.48，<0.001），I-IIA期肺癌患者的miRNA-30a相对表达也高于IIB-IV期患者（分别为0.98±0.64和0.66±0.54，<0.05）。此外，miRNA-30a能够区分良性肺部疾病和肺癌，ROC曲线下面积（AUC）为0.822。ROC分析还显示，基于约登指数的I-IIA期腺癌最佳截断点的AUC为0.875。因此，BALF中miRNA-30a水平升高可能是诊断非小细胞肺癌的有用生物标志物。
